Document Type : RESEARCH PAPER
1 Department of orthopedics, Taleghani Hospital Research Development committee, Shahid Beheshti University of medical sciences, Tehran, Iran 2 Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA
Department of Orthopedic Surgery, Clinical Research Development Unit of Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Bone and Joint reconstruction research center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Objectives: The epidemiology of osteosarcoma (OS), the most common primary bone sarcoma, was not
evaluated in the Middle East. Therefore, this study aimed to examine the incidence, demographic
characteristics, epidemiology, and survival rate of patients with different subtypes of OS, based on data
derived from the Iran National Cancer Registry (INCR) to evaluate the influence of ethnicity and race.
Methods: All OS patients registered in the INCR between March 20, 2008, and March 20, 2014, were enrolled in
this study, and information such as age, gender, cancer location, OS subtype, and survival time were evaluated
Results: The Age-Standardized Incidence Rate (ASIR) for OS was 3.02 per million person-years, with a mean age
of 25.6 years and a male-female ratio of 1.54:1. Not Otherwise Specified (NOS) OS, chondroblastic OS, and central
OS had the highest frequencies among the subtypes of OS. The overall one-, three-, and five-year survival rates
were 87%, 61%, and 49%, respectively, with a mean duration of 6.16 years.
Conclusion: The ASIR of OS in our country was similar to that in the US and higher than that in China. The peak
frequency was between 15-19 years old. The male-female ratio in our patients was higher than the OS gender ratio
in most series. Although it was not statistically significant, older age at the time of diagnosis, axial location, and male
gender were the poorest prognosis factors.
Level of evidence: III